• By ICR Secretariat
  • Posted Tuesday, July 9, 2019

Pfizer muscular dystrophy gene therapy stumbles on safety

https://www.biopharmadive.com/news/pfizer-muscular-dystrophy-gene-therapy-stumbles-on-safety/557901/

Pfizer's Duchenne muscular dystrophy gene therapy improved physical function in two patients measured one year after treatment, but also led to one patient being hospitalized for severe kidney complications.